Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction – Full Text View – ClinicalTrials.gov

Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction – Full Text View – ClinicalTrials.gov

BREAKING NEWS


2020/03/28 Reven News Press

A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix [...]

REVEN

is a global healthcare company with more than

10 years of innovation and leadership in vascular care.

In 2019, Reven completed their single-ascending-dose (SAD)/multiple-ascending-dose(MAD) Phase 1 Clinical Trial in the United States. Reven is now in the planning stage of their Phase 2 Clinical Trial that will be conducted in the United States in Q2/Q3 of 2020.